Overview
U.S. spinal surgical solutions provider's Q4 revenue grew 3% yr/yr; full-year revenue up 14%
Company returned to profitability in Q4, with net income of $0.1 mln
Q4 revenue impacted by sale of non-core assets to Companion Spine
Outlook
Xtant Medical expects 2026 revenue between $95 mln and $99 mln
Company expects organic growth in core biologics business in 2026
Xtant Medical expects to be free cash flow positive in 2026
Result Drivers
ASSET SALE IMPACT - Q4 revenue reduced by earlier-than-anticipated closing of Companion Spine transaction, resulting in one less month of Coflex and CoFix sales and related international hardware sales
LICENSE REVENUE - Higher license revenue contributed to Q4 topline, partly offsetting impact from asset sale
SALES MIX AND SCALE - Gross margin improvement attributed to sales mix and greater scale, partially offset by increased charges for excess and obsolete inventory
Company press release: ID:nPn56XYYca
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | $32.40 mln | ||
Q4 EPS | $0 | ||
Q4 Net Income | $100,000 |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Xtant Medical Holdings Inc is $1.35, about 152.6% above its March 27 closing price of $0.53
The stock recently traded at 109 times the next 12-month earnings vs. a P/E of 87 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments